Robbins Arroyo LLP: Intercept Pharmaceuticals, Inc. (ICPT) Misled Shareholders According to a Recently Filed Class Action

SAN DIEGO & NEW YORK--(BUSINESS WIRE)-- Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Intercept Pharmaceuticals, Inc. (NasdaqGS: ICPT). The complaint is brought on behalf of all purchasers of Intercept securities between May 31, 2016 and September 20, 2017, for alleged violations of the Securities Exchange Act of 1934 by Intercept's officers and directors. Intercept, a biopharmaceutical company, develops and commercializes therapeutics to treat non-viral, progressive liver diseases. The company's lead product candidate is Ocaliva (obeticholic acid).

View this information on the law firm's Shareholder Rights Blog:

Intercept Accused of Failing to Disclose Major Risks Associated With Its Drug

According to the complaint, on May 31, 2016, Intercept announced that the U.S. Food and Drug Administration ("FDA") had approved Ocaliva to treat patients with primary biliary cholangitis ("PBC"). Intercept further stated that Ocaliva fills an important unmet need for PBC patients who have had an inadequate response or are intolerant to the only other approved treatment. Intercept repeatedly touted the drug's promising abilities in its public statements while failing to report that Ocaliva had undisclosed safety risks, including death, to patients suffering from PBC. On September 21, 2017, the FDA issued a safety announcement warning doctors after reports of multiple deaths linked to the drug. The FDA specifically cautioned that Ocaliva is being incorrectly dosed in patients with moderate to severe decreases in liver function, resulting in an increased risk of serious liver injury and death, and that Ocaliva may be associated with injury in some patients who are receiving the correct dose. On this news, Intercept's stock fell $24.42 per share, or nearly 25%, to close at $73.70 per share on September 21, 2017.

Intercept Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171009005863/en/

Robbins Arroyo LLP
Leonid Kandinov
(619) 525-3990 or Toll Free (800) 350-6003

Source: Robbins Arroyo LLP

More From Press Releases